profit from every $100 of sales.
$0$100
Curis
$0.59-9.42% today
-97.6% in 1 year
1-year low $0.381-year high $27.40
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Curis sold, what it kept, and what it did with the cash.
Sales went from $10.2 million in 2022 to $9.44 million in 2025, with -$7.58 million of profit last year.
SalesProfit
Curis vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Curis | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Curis's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 10 | 10 | 11 | 9 | |
| 10 | 10 | 11 | 9 | |
| -53 | -48 | -45 | -33 | |
| -52 | -45 | -43 | -5 | |
| -57 | -47 | -43 | -8 | |
| -12.20 | -8.96 | -6.88 | -0.58 | |
| 97.5% | 97.9% | 99.1% | 99.5% | |
| -521.7% | -482.2% | -408.3% | -348.4% | |
| -557.7% | -473.0% | -397.8% | -80.3% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 109 | 77 | 41 | 20 |
| Cash | 20 | 27 | 20 | 5 |
| Total debt | 4 | 3 | 3 | 2 |
| Total liabilities | 62 | 58 | 47 | 15 |
| 47 | 20 | -6 | 5 | |
| 5 | 5 | 6 | 13 | |
| -81.2% | -159.6% | – | -60.2% | |
| -121.7% | -241.0% | 723.4% | -138.8% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -54 | -38 | -40 | -27 | |
| 0 | – | – | – | |
| -55 | -38 | -40 | -27 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 7 | 6 | 6 | 4 |
Valuation
- –
- –
- –
- 13.5×
- 0.4×
- –
- –
- -688.5%
- -191.9%
- 0.0%
Profitability
- 99.5%
- -348.4%
- -80.3%
- -355.4%
- -696.0%
- 189.5%
- 101.7%
- -38.0%
- -558.6%
- 299.2%
Growth
- −2.4%
- –
- +31.2%
- –
- +131.6%
Financial health
- -0.7×
- 0.30
- 8.1%
- -104.8×
- 0.36
- 0.36
- 0.47
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 13%of 889
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 12, 2026 | -1.25 | -0.29 | −331.0% |
| Mar 19, 2026 | -0.50 | -0.44 | −14.7% |
| Nov 6, 2025 | -0.49 | -0.62 | +21.0% |
| Aug 5, 2025 | -0.68 | -1.99 | +65.8% |
| May 6, 2025 | -1.25 | -1.14 | −9.6% |
| Mar 31, 2025 | -1.25 | -1.36 | +8.1% |
| Nov 14, 2024 | -1.70 | -1.88 | +9.6% |
| Aug 1, 2024 | -2.03 | -1.70 | −19.4% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
4/7Passes 4 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
69Pass
Benjamin Graham
23No pass
Philip Fisher
61Pass
Peter Lynch
30No pass
Joel Greenblatt
4No pass
Charlie Munger
69Pass
Terry Smith
63Pass
Questions about Curis
Is Curis a good stock to buy?
A business with weak numbers that is not profitable yet. 4 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Curis AI analysis
What does Curis do?
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. It is in Biotechnology.
Does Curis pay a dividend?
No. Curis does not pay a dividend at the moment.
Is Curis stock halal?
No. Curis does not pass our halal screen: its debt is 41% of its market value, at or above the 33% limit. How we check
How has Curis stock done over the past year?
Down 97.6% over the past twelve months, to $0.59. It traded between $0.38 and $27.40 and is 97.8% below its high.
Who are Curis's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Curis's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.